about
Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case-control studyCis- and trans-acting gene regulation is associated with osteoarthritisThe serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigensDecrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritisAutologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cellsMultiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseasesAnalysis of immunoglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjögren's syndrome.Perspectives and limitations of gene expression profiling in rheumatology: new molecular strategiesDifferential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosusThe changing landscape of biosimilars in rheumatologyBiologicals in rheumatoid arthritis: current and futureThe unmet need in rheumatology: reports from the Targeted Therapies meeting 2016Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementEULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteriaA prospective pilot study to evaluate an animated home-based physical exercise program as a treatment option for patients with rheumatoid arthritis.Sinusoidal dilatation: a rare side effect of azathioprineUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Targeting GM-CSF in rheumatoid arthritisCirculating proteasomes are markers of cell damage and immunologic activity in autoimmune diseasesMutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritisThe p68 autoantigen characteristic of rheumatoid arthritis is reactive with carbohydrate epitope specific autoantibodiesThe US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy.Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger jointsProspective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints.First clinical evaluation of sagittal laser optical tomography for detection of synovitis in arthritic finger joints.Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reductionIdentification of known and novel genes in activated monocytes from patients with rheumatoid arthritis.Remission and rheumatoid arthritis: data on patients receiving usual care in twenty-four countries.Splenic proliferative lymphoid nodules distinct from germinal centers are sites of autoantigen stimulation in immune thrombocytopenia.SiPaGene: A new repository for instant online retrieval, sharing and meta-analyses of GeneChip expression dataHomeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus.Defining TNF-α- and LPS-induced gene signatures in monocytes to unravel the complexity of peripheral blood transcriptomes in health and disease.Disturbed microcirculation in the hands of patients with systemic sclerosis detected by fluorescence optical imaging: a pilot studyRituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patientsAngiotensin receptor type 1 and endothelin receptor type A on immune cells mediate migration and the expression of IL-8 and CCL18 when stimulated by autoantibodies from systemic sclerosis patientsAccess to disease modifying treatments for rheumatoid arthritis patients.Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence testsConsensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis.Shwartzman phenomenon in a patient with active systemic lupus erythematosus preceding fatal disseminated intravascular coagulation.Upregulation of immunoproteasome subunits in myositis indicates active inflammation with involvement of antigen presenting cells, CD8 T-cells and IFNΓ
P50
Q21195665-60F5C015-6A5D-46F6-8C36-554B6F11F2A5Q24546386-8013556F-28F1-4C31-A52E-CAD81F2F35F3Q24646963-D5C70FE4-B716-4EB5-A9AD-61F6ADEA20C9Q24684384-5513F36C-DA8A-408F-851F-0AEB12FB0373Q24792552-CE2BEBDE-3F85-4136-A403-B8212AC5EABDQ24793730-A4B4A50B-FB73-4787-9F48-EB821DD8BF6CQ24800884-B91244C5-FBC5-4FA6-B3D6-37BD7EF2B354Q24805489-3491516E-58C2-4D68-B5A7-EA4969D30CB6Q24812278-41E0ABE5-A334-4FDB-BB01-46F9A8E3BDAAQ26766515-99C24202-0F9E-43BB-B89E-3D9B6091D3DBQ26780316-81064C67-5E89-40CB-90F8-61B3E3397A71Q27007783-36AF67D2-101C-4791-A4F8-4F84C47D6B00Q27021115-82D6409D-7C4C-4EA6-9E9E-88EFE3C4D517Q27026582-FDCE5425-7103-4989-8C7C-A2A30662DF73Q27309258-63F08911-F4CF-44BE-82A9-309E6632D0B0Q27477929-DA4F72AF-8D67-4F8E-8FC7-D245304DBBFFQ27691388-6DBB71EB-5D0F-4CD7-8583-FB9DF1DEC584Q28067377-445A8038-8E3A-494C-AABE-C9422CC70572Q28206786-B84C727E-0507-4DF4-A0CA-1D616DD34877Q28238667-99EBAF57-DB78-46F5-9018-ADBF1EF2C2CCQ28368414-86BA6D16-3D36-48EC-9C03-DA6645A606E1Q30453312-0CACB1DE-E628-4231-8DD7-0A525FCA704EQ30489871-BD0C0213-09DF-4EFE-9132-A98D1D2F373BQ30500517-3AE4F90B-31CE-44AB-BA3B-F8D4EFB098BEQ31105353-AA763AA2-D081-47DF-B8D5-8A830843E50FQ31119751-6E095D15-96D6-41C5-B7AD-83F3C96C30C1Q33180160-1F1391EC-9CD9-4225-914F-FB1163A8E422Q33365103-4B22A3E7-A295-44D8-8454-9763B853746BQ33403170-610B0C52-1EB0-47C1-B858-9575D1C26494Q33415370-7CBD1D2C-CE65-4EA2-82FC-D6DBDCD30089Q33591655-CD376C47-BDE5-4843-8A68-DEBB61CDC388Q33635438-D366238C-570D-4675-A4F7-44A29B343B95Q33651547-9B25F5B3-6009-4216-90BA-A7F8B78090CCQ33765608-1B321C12-340F-42CB-960D-153ACDA5DFA9Q33765684-C528B484-EBFA-40E0-92D3-E95A92F01AF9Q33782402-C31DB5F1-12C9-4076-9032-1B1FFB5644CDQ33923278-69A44D2E-3BC8-45D4-86D7-91357050F475Q33954663-28288B6F-18A7-4C6D-891D-AAFC469143EEQ33959460-24267BB1-C364-4EDC-9D50-D1451B02993AQ34010999-57A134F0-A62B-45AD-869E-6FBCF9D274A5
P50
description
German rheumatologist
@en
deutscher Rheumatologe
@de
name
Gerd-Rüdiger Burmester
@ast
Gerd-Rüdiger Burmester
@de
Gerd-Rüdiger Burmester
@en
Gerd-Rüdiger Burmester
@nl
Gerd-Rüdiger Burmester
@sl
type
label
Gerd-Rüdiger Burmester
@ast
Gerd-Rüdiger Burmester
@de
Gerd-Rüdiger Burmester
@en
Gerd-Rüdiger Burmester
@nl
Gerd-Rüdiger Burmester
@sl
altLabel
Gerd-R Burmester
@en
prefLabel
Gerd-Rüdiger Burmester
@ast
Gerd-Rüdiger Burmester
@de
Gerd-Rüdiger Burmester
@en
Gerd-Rüdiger Burmester
@nl
Gerd-Rüdiger Burmester
@sl
P1006
P1015
P214
P227
P244
P268
P269
P349
P1005
P1006
P1015
P106
P1207
n2012147926
P21
P213
0000 0000 8188 4709
P214
P227
P244
n2002133884